Literature DB >> 17287410

Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Wolfgang Saeger1, Dieter K Lüdecke, Michael Buchfelder, Rudolf Fahlbusch, Hans-Jürgen Quabbe, Stephan Petersenn.   

Abstract

In 1996, the German Registry of Pituitary Tumors was founded by the Pituitary Section of the German Society of Endocrinology as a reference center for collection and consultant pathohistological studies of pituitary tumors. The experiences of the first 10 years of this registry based on 4122 cases will herein be reported. The data supplement former collections of the years 1970-1995 with 3480 surgically removed tumors or lesions of the pituitary region. The cases were studied using histology, immunostainings and in some cases also molecular pathology or electron microscopy. The adenomas were classified according to the current World Health Organization classification in the version of 2004. From 1996 on 3489 adenomas (84.6%), 5 pituitary carcinomas (0.12%), 133 craniopharyngiomas (3.2%), 39 meningiomas (0.94%), 25 metastases (0.6%), 22 chordomas (0.5%), 115 cystic non-neoplastic lesions (2.8%), and 46 inflammatory lesions (1.1%, 248 other lesions or normal tissue (6.0%)) were collected by us. The adenomas (100%) were classified into densely granulated GH cell adenomas (9.2%), sparsely granulated GH cell adenomas (6.3%), sparsely granulated prolactin (PRL) cell adenomas (8.9%), densely granulated PRL cell adenomas (0.3%), mixed GH/PRL cell adenomas (5.2%), mammosomatotropic adenomas (1.1%), acidophilic stem cell adenomas (0.2%), densely granulated ACTH cell adenomas (7.2%), sparsely granulated ACTH cell adenomas (7.9%), Crooke cell adenomas (0.03%), TSH cell adenomas (1.5%), FSH/LH cell adenomas (24.8%), null cell adenomas (19.3%), null cell adenoma, oncocytic variant (5.8%), and plurihormonal adenomas (1.3%). Following the WHO classification of 2004, the new entity 'atypical adenoma' was found in 12 cases in 2005. Various prognostic parameters and clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287410     DOI: 10.1530/eje.1.02326

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  131 in total

Review 1.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  Efficient, specific, developmentally appropriate cre-mediated recombination in anterior pituitary gonadotropes and thyrotropes.

Authors:  María Inés Pérez-Millán; Michael G Zeidler; Thomas L Saunders; Sally A Camper; Shannon W Davis
Journal:  Genesis       Date:  2013-09-02       Impact factor: 2.487

3.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

4.  Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.

Authors:  Yoshikazu Ogawa; Mika Watanabe; Teiji Tominaga
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

5.  Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.

Authors:  Genya Aharon-Hananel; Ruth Percik; Muhamad Badarna; Inbal Uri; Amit Tirosh
Journal:  Endocrine       Date:  2019-07-02       Impact factor: 3.633

6.  Nelfinavir induces radiation sensitization in pituitary adenoma cells.

Authors:  Jing Zeng; Alfred P See; Khaled Aziz; Saravanan Thiyagarajan; Tarek Salih; Rajendra P Gajula; Michael Armour; Jillian Phallen; Stephanie Terezakis; Lawrence Kleinberg; Kristen Redmond; Russell K Hales; Roberto Salvatori; Alfredo Quinones-Hinojosa; Phuoc T Tran; Michael Lim
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

7.  Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.

Authors:  Jillian Maclean; Matthew Aldridge; Jamshed Bomanji; Susan Short; Naomi Fersht
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

8.  A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment.

Authors:  Yoshikazu Ogawa; Teiji Tominaga
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

9.  Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.

Authors:  Emilija Manojlovic-Gacic; Milica Skender-Gazibara; Vera Popovic; Ivan Soldatovic; Novica Boricic; Savo Raicevic; Sandra Pekic; Mirjana Doknic; Dragana Miljic; Irina Alafuzoff; Fredrik Pontén; Olivera Casar-Borota
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 10.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.